Hengrui Medicine (01276.HK): Marketing Authorization Application for Relugolix Tablets Accepted by EMA
NewTimeSpace News: On June 22, 2026, Hengrui Medicine (01276.HK) issued an announcement stating that the European Medicines Agency has formally validated and accepted the marketing authorization application submitted by the company for Relugolix Tablets.
As disclosed in the announcement, Relugolix Tablets is a second-generation androgen receptor (AR) inhibitor, intended for use in combination with androgen deprivation therapy (ADT) in adult male patients diagnosed with metastatic hormone-sensitive prostate cancer with high tumour burden. The company reminded that the timeline and outcome of the EMA review remain uncertain. Drug development and commercialization involve a lengthy, multi-stage process with inherent risks and uncertainties.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Hengrui Medicine (01276.HK) Adebrelimab Becomes First Domestic PD-L1 Inhibitor for NSCLC Perioperative Setting
- Hengrui Medicine (01276.HK): SHR-6914 Injection Approved for Clinical Trials
- CMA LOGISTICS (01292.HK): changes English company name and stock short name, to trade as "CM LOGISTICS" from 27 August
- HENGRUI PHARMA (01276.HK): SHR-7012 Injection Receives Clinical Trial Approval for Treating Cutaneous Lupus Erythematosus
- GF SEC (01776.HK): 2025 short-term corporate bond (Tranche 8) "25GFD10" to be redeemed with interest and delisted on 24 August
